That is correct. I believe Astrazeneca flew out a team to do due...

That is correct. I believe Astrazeneca flew out a team to do due diligence. What they discovered was a poorly capitalised company. a poorly qualified Board, poor patent coverage and trial results from just 23 patients. It has taken 6 years to get to this drug back on track to possibly recoup the 100 million plus shareholders have tipped into it. Most of my shares were purchased at $3. Greg Collier did a deal on Chemgenix in 2011 for 230 million, he needs to do another for CPN10. We don't want more capital raisings at 3 cents or 7.5 cents, and we don't need the issueing of millions of options for directors or related parties.